Dr Bearss will continue to lead SuperGen’s discovery and preclinical development strategies and execution as SuperGen continues to accelerate the discovery and advancement into the clinic of novel drug candidates, the company said. His responsibilities will include the oversight of target selection, product creation and early stage development.
Dr Bearss joined SuperGen as a result of the company’s acquisition of Montigen Pharmaceuticals in 2006.
James Manuso, chairman, president and CEO of SuperGen, said: “As we move deeper into the frontiers of novel pharmaceutical space to address unmet medical needs, and expand our proprietary portfolio, Dave’s scientific vision and leadership, and his extensive R&D experience, will continue to enable our company to rapidly and efficiently identify, create and advance new drug candidates.”